Welcome to ROADMAP!
The “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform” (ROADMAP) project aimed to provide the foundation for an integrated data environment and framework for real-world evidence (RWE in Alzheimer’s disease).
This included the development of consensual key outcome measures and enabling data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP had a budget of EUR 8.21 million and 26 partners led by the University of Oxford and Novartis. The project ran from September 2016 till October 2018.
NH
Latest News
“Successfully delivering therapies to the tens of millions in need will depend on building a sustainable approach that addresses the challenges and opportunities around treatment access at time of approval. In AD this will very much depend on the integration of real-world evidence (RWE) within health care systems to support evidence for approval as well as Health Technology Assessment and funding allocation.”
Project Leader and WorldWide Market Access Director NS at Novartis
Frédéric de Reydet de Vulpillieres
“During the project, the partners will involve diverse stakeholders (patients, carers, regulators, HTA bodies, payers, industry and researchers) to identify and prioritise possible outcomes of clinical trials with regard to their individual relevance but also health-economic importance. Using the information from the different cohorts and databases, new and ground-breaking analyses will be developed and realised.”
Subscribe to our newsletter!
